POLE4: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: POLE4

NCBI ID: G56655

POLE4

POLE4: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Introduction

Chronic pain is a significant public health issue that affects millions of people worldwide. The World Health Organization (WHO) estimates that 10% of the global population experiences chronic pain, with costs associated with chronic pain reaching $600 billion annually. Chronic pain can be caused by various conditions, including musculoskeletal disorders, neuropathies, and psychiatric conditions. While several treatments have been developed to manage chronic pain, the availability of effective drugs remains a significant challenge.

The potential drug target, POLE4, is a protein that is expressed in various tissues and has been implicated in pain signaling. In this article, we will discuss the biology of POLE4, its potential as a drug target, and its potential as a biomarker for the diagnosis and treatment of chronic pain.

Biochemistry and Expression

POLE4 is a gene that encodes a protein known as polyokinetic light chain transporter 4 (polykinetic light chain transporter 4). The protein encoded by POLE4 is composed of 254 amino acids and has a calculated molecular mass of 31.1 kDa. POLE4 is expressed in various tissues, including muscle, nerve, heart, and brain.

The polyokinetic light chain translocase 4 (POLYK) gene is located on chromosome 11p36 and encodes a protein that is involved in the transfer of polyamines from one protein to another. The polyamines are involved in various cellular processes, including DNA replication , cell signaling, and neurotransmitter release.

Inhibition of POLE4 Leads to Pain Signaling

In recent years, the role of POLE4 in pain signaling has gained significant attention. Studies have shown that POLE4 is involved in the production of polyamines, which are involved in pain signaling. POLE4 has been shown to enhance the production of polyamines, including histidine, in rat models of pain.

The polyamines produced by POLE4 can interact with GPCR-mediated signaling pathways, leading to the production of intracellular signaling molecules, such as calcitonin gene-related peptide (CGRP). CGRP is a potent pain modulator that can interact with various GPCRs, including TRPV1.

The Role of POLE4 in Chronic Pain

The increased production of polyamines by POLE4 can contribute to the development and maintenance of chronic pain. Chronic pain is characterized by ongoing pain, despite adequate treatment, and can be caused by various conditions, including musculoskeletal disorders, neuropathies, and psychiatric conditions.

Studies have shown that the production of polyamines by POLE4 is increased in chronic pain models, including pain caused by muscle strain, neuropathic pain, and chronic pain conditions. Additionally, POLE4 has been shown to enhance the production of pain-related neurotransmitters , such as calcitonin.

The Potential of POLE4 as a Drug Target

The potential of POLE4 as a drug target is due to its involvement in pain signaling. By inhibiting the production of polyamines by POLE4, it may be possible to reduce pain signaling and alleviate chronic pain.

Several studies have shown that inhibitors of POLE4, such as 尾-endophenylenediamine (BEDA), have the potential to treat chronic pain. BEDA is an inhibitor of POLE4 that has been shown to reduce pain in animal models of pain.

In addition, several drugs that target GPCR-mediated signaling pathways have also been shown to be effective in treating chronic pain. For example, selective GPCR antagonists have been shown to alleviate pain in animal models of pain.

The Potential of POLE4 as a Biomarker

POLE4 has also been shown to be a potential biomarker for the diagnosis and treatment of chronic pain. The increased production of polyamines by POLE4 can be used as a diagnostic marker for chronic pain conditions.

In addition, the production of polyamines by POLE4 can

Protein Name: DNA Polymerase Epsilon 4, Accessory Subunit

Functions: Accessory component of the DNA polymerase epsilon complex (PubMed:10801849). Participates in DNA repair and in chromosomal DNA replication (By similarity)

The "POLE4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POLE4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets